TSL Thinksmart Limited

RNS Number:7040D
Tissue Science Laboratories PLC
13 November 2002

                                                                13 November 2002



            TSL signs Italian distribution agreement with SEDA



Tissue Science Laboratories plc ('TSL'), the medical devices company
specialising in human tissue replacement and repair, today announces that it has
signed its first European distribution agreement with SEDA, Italy's largest
independent distributor of medical products, to distribute TSL's PermacolTM
products to the Italian market.  No financial details were disclosed.



As a result of this agreement, TSL's technology (porcine dermis derived surgical
implants in both sheet and injectable forms for soft tissue repair and
reconstruction) will gain exposure to a wide audience of medical professionals,
including maxillo-facial, ENT & plastics specialists and general surgeons,
through a well-respected distributor in the Italian market.  With more than 20
years experience within the medical device market in Italy, SEDA has developed
an excellent reputation within the surgical community for introducing innovative
products into this market.  With a specialist sales team of 25, SEDA will
vigorously promote PermacolTM Surgical Implant (SI) for maxillo-facial, ENT,
plastics and general surgery applications and PermacolTM Injection for urethral
bulking in the treatment of female stress incontinence.



SEDA's objective is to promote surgical techniques using PermacolTM, instead of
the synthetic materials currently used, to significantly improve patient
outcomes during major surgical procedures.  SEDA's experience of the Italian
market and its diversified portfolio, which already covers many of the different
surgical areas in which PermacolTM is used, fits well with TSL's strategy for
the Continental European market.



Commenting on the agreement, Sergio Zarelli, President of SEDA, Italy, said:

"We are excited about bringing TSL's products to the Italian market.  This
agreement underlines our commitment to introducing the best new biomaterials to
Italy.  We believe that PermacolTM offers surgeons a viable, natural
alternative to the synthetic materials currently used."



Martin Hunt, CEO of TSL, said:

"This is our first agreement with a European distributor and we are delighted to
have attracted a partner of the calibre of SEDA, which has an excellent
reputation for promoting new innovative surgical products to surgeons in Italy.
SEDA has the breadth of operation to be able to promote the range of TSL's
products and to establish our presence in the Italian market."



                                     -Ends-



Enquiries:


TSL plc                                                  Tel:  01252 333 002
Martin Hunt, Chief Executive Officer
David Jennings, Finance Director
Financial Dynamics                                       Tel:  020 7831 3113
Samantha Robbins





Notes to Editors



Background on TSL



Founded in 1995 with headquarters in Aldershot, Hampshire, TSL has used its
proprietary technology to launch successfully two different formulations of the
product and build a development pipeline that addresses the large and fast
growing surgical implant and woundcare markets.  The Company floated in November
2001 and is listed on the Alternative Investment Market.



TSL has a family of products based on the same core technology.  Each product
has been adapted, with unique properties, to make it suitable for use in
different applications.  PelvicolTM/PermacolTM Surgical Implant (SI) is sold
by Bard in the US and Europe for urology and gynaecology applications;
PermacolTM SI (general surgery) is sold for complex hernia repair in the US and
Europe; PermacolTM SI (ENT, plastic and reconstruction) is sold in Europe for
head and neck applications, with an expected US launch in 2003; PermacolTM
Injection (UBA) is an injectable form of PermacolTM used as a urethral bulking
agent to treat female stress incontinence.  Further variations of the sheet and
injectable forms of PermacolTM are being developed for facial augmentation and
reconstruction, and wound therapy applications.



Background on SEDA



SEDA's business objectives are the research, selection and distribution within
the Italian healthcare market of medical consumables, electro-medical equipment
and the most technologically advanced surgical devices. Since 1973 SEDA has
specialised in the areas of cardiosurgery, cardiology, orthopaedics,
anaesthesia, ENT and general surgery. Patient care has always been one of SEDA's
main concerns, which they have addressed through the introduction of new and
efficient techniques. With more than twenty years experience and constantly
growing, not only in terms of turnover and employees, but especially quality of
service, SEDA has been able to satisfy customer demands at the highest level by
adapting to and often anticipating evolutions in the market.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGREAKFAFSNAFFE

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Lug 2023 a Lug 2024